TABLE 2.
Comparison of the Average Estimated Prostate Volumes and PSADs Between 100 Non-PCa and 53 High-Gleason-Sum (Gleason Score ≥ 7) PCa Patients
| Variable | Non-PCa | High-Gleason-sum PCa | P-valuea |
|---|---|---|---|
| Total prostate volume (cm3) | 67.0 ± 42.3 | 44.2 ± 19.5 | 0.00002 |
| PZ volume (cm3) | 21.5 ± 6.7 | 19.7 ± 6.0 | 0.07 |
| CG volume (cm3) | 45.5 ± 39.0 | 24.5 ± 17.2 | < 0.00001 |
| CG ratio | 0.62 ± 0.13 | 0.52 ± 0.11 | < 0.00001 |
| PSA (ng/mL) | 8.7 ± 6.3 | 10.9 ± 13.9 | 0.2 |
| PSAD (ng/mL/cm3) | 0.15 ± 0.12 | 0.25 ± 0.25 | 0.001 |
| PSAD-CG (ng/mL/cm3) | 0.26 ± 0.24 | 0.51 ± 0.55 | 0.00002 |
PSA: prostate-specific antigen; PCa: prostate cancer; PZ: peripheral zone; CG: central gland; PSAD: PSA density; PSAD-CG: CG volume-adjusted PSA.
a
A critical value of 0.05 was used for statistical significance; after Bonferroni correction, the critical value was adjusted to 0.05/7 = 0.007.